Johnson & Johnson Reports Q2 Earnings Beat Driven by Strong Performance of Medicines Unit

Johnson & Johnson reported second-quarter earnings and revenue that exceeded expectations, driven primarily by strong performance in its Innovative Medicine segment. The company raised full-year guidance as sales from key pharmaceutical products like Darzalex and Tremfya surged significantly.

By Cris Tolomia Wed, July 15, 2026 at 3:01 PM GMT+3 2 min read · Yahoo Finance · July 15, 2026, 12:01 UTC

Tickers: $JNJ

Topics: earnings guidance update pharmaceuticals revenue growth

Read the full article at Yahoo Finance

More World news

BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC
OpenAI Secures $15 Billion in New Funding at $1.25 Trillion Valuation Seeking Alpha · November 12, 2026, 15:13 UTC
Digi International Shares Fall 18% Following Fiscal Q4 Earnings Release Seeking Alpha · November 12, 2026, 15:13 UTC
Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events PR Newswire · November 12, 2026, 15:15 UTC
Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC
Pomerantz Law Firm Investigates Innodata Inc. Following Mass Layoffs and Stock Price Drop PR Newswire · November 12, 2026, 15:10 UTC